The bipartisan 340B Drug Pricing Program has supported affordable drugs and services to vulnerable patients since 1992 – at nearly no cost to taxpayers. But pending regulations would dramatically narrow access to the program, hurting patients and putting entire communities at risk of losing vital services, such as trauma care and emergency preparedness.

Read Our View: 340B Benefits Vulnerable Patients, Essential Hospitals, Taxpayers

View our infographic: 340B Guidance: When a Patient is Not a Patient